Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Amortization of Deferred Charges (2021 - 2025)

Historic Amortization of Deferred Charges for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $1.2 million.

  • Oncology Institute's Amortization of Deferred Charges fell 2615.0% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 3956.71%. This contributed to the annual value of $6.3 million for FY2024, which is 161.16% up from last year.
  • Latest data reveals that Oncology Institute reported Amortization of Deferred Charges of $1.2 million as of Q3 2025, which was down 2615.0% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Amortization of Deferred Charges registered a high of $4.9 million during Q1 2025, and its lowest value of $17000.0 during Q2 2021.
  • For the 5-year period, Oncology Institute's Amortization of Deferred Charges averaged around $1.4 million, with its median value being $1.5 million (2022).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 485555.56% in 2022, then crashed by 2785.94% in 2025.
  • Oncology Institute's Amortization of Deferred Charges (Quarter) stood at $18000.0 in 2021, then soared by 8522.22% to $1.6 million in 2022, then rose by 1.29% to $1.6 million in 2023, then increased by 1.4% to $1.6 million in 2024, then dropped by 26.47% to $1.2 million in 2025.
  • Its Amortization of Deferred Charges was $1.2 million in Q3 2025, compared to $1.1 million in Q2 2025 and $4.9 million in Q1 2025.